SCHEMBL22990507

SCHEMBL22990507

Cn1ccc(Br)c(C(F)(F)F)c1=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.34
TAF1 P21675 1/20 0.34
BRPF1 P55201 1/20 0.34
CREBBP Q92793 1/20 0.34
CECR2 Q9BXF3 1/20 0.34
BRD9 Q9H8M2 1/20 0.34
HCAR1 Q9BXC0 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
CHRNB2 P17787 1/20 0.32
CHRNB4 P30926 1/20 0.32
CHRNA3 P32297 1/20 0.32
CHRNA4 P43681 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
CYP2C9 P11712 1/20 0.32
CRBN Q96SW2 1/20 0.31
KDM4E B2RXH2 1/20 0.30
ALDH1A1 P00352 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22981490 0.77 CYP2C9 (0.37) BRD4TAF1BRPF1CREBBPCECR2
SCHEMBL25344358 0.74 BRD9 (0.37) BRD4TAF1BRPF1CREBBPCECR2
SCHEMBL26831959 0.73 BRD4 (0.34) BRD4TAF1BRPF1CREBBPCECR2
SCHEMBL2594416 0.73 BRD9 (0.39) BRD4TAF1BRPF1CREBBPCECR2
SCHEMBL29911927 0.71 BRD9 (0.38) BRD4TAF1BRPF1CREBBPCECR2
SCHEMBL29565072 0.71 SCD (0.35) GAA
SCHEMBL19785547 0.69 BRD9 (0.37) BRD4TAF1BRPF1CREBBPCECR2
SCHEMBL31439950 0.69 ATAD2 (0.39) BRD4TAF1BRPF1CREBBPCECR2
SCHEMBL29565022 0.69 NOTUM (0.32) BRD4
SCHEMBL1076952 0.68 GRM2 (0.54)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4010334-A1 HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS Novartis AG (CH) 2022-06-15 EP disclosed
WO-2021026672-A1 HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS NOVARTIS AG (CH) 2021-02-18 WO disclosed
WO-2021028806-A1 HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS NOVARTIS AG (CH) 2021-02-18 WO disclosed
CN-108558889-A Bu Luomo structural domain inhibitor 赛尔基因昆蒂赛尔研究公司 2018-09-21 CN disclosed
CN-108137539-A SUBSTITUTED BENZIMIDAZOLES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS 尼奥迈德研究所 2018-06-08 CN disclosed